REG - BioVentix PLC - Board Appointment

BioventixAnnouncement

30/05/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230530:nRSd8774Aa&default-theme=true

RNS Number : 8774A  BioVentix PLC  30 May 2023

Bioventix plc

("Bioventix" or the "Company")

 

Board Appointment

 

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics is delighted to announce that it has appointed Joanne
(Jo) Pisani to the Board, as an independent Non-Executive Director, with
immediate effect. Jo will chair the Company's Audit Committee.

Jo is a chartered engineer with a distinguished background in the
Pharmaceutical, Life Sciences and Biotech sectors. She has held roles at GSK
and BP in strategy, commercial and operational functions before working in
strategic consultancy. She led PwC's UK Pharmaceutical and Life Sciences
practice, assisting clients with developing strategy, designing and
implementing transformational change and completing M&A transactions.

Jo is a passionate supporter of critical public health issues, such as
tackling dementia, rare diseases and anti-microbial resistance. She focuses on
supporting charities, universities and business start-ups. She is chair of
Birmingham's Precision Health Technology Accelerator and also chairs the
Advisory Board for London's MedCity. She serves on the boards of the UK
Dementia Research Institute, LifeArc, The RSA Group, London and Partners and
Beacon.  She is also a Non-Executive Director and strategic advisor to
biotech companies in the UK, Finland and Spain

Ian Nicholson, Chairman, commented: "The Board is delighted to welcome Jo to
Bioventix. She brings considerable leadership and strategic experience in Life
Sciences and biotech businesses, large and small, that is highly relevant to
Bioventix and the opportunities being addressed by the Company. I am confident
that she will add considerable value to the Company."

 

 

For further information please contact:

 Bioventix plc                                      Tel: 01252 728 001

 Peter Harrison           Chief Executive Officer

 Bruce Hiscock            Chief Financial Officer

 finnCap Ltd                                        Tel: 020 7220 0500

 Geoff Nash/Simon Hicks   Corporate Finance

 Alice Lane               ECM

 

 

 

Regulatory disclosures

INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM
RULES FOR COMPANIES ("AIM RULES")

 Full name:                                                    Joanne (Jo) Patra Pisani
 Age:                                                          58
 Shareholding in the Company:                                  No shares held
 Current directorships and partnerships:

                                                               UK DRI Ltd

                                                               Beacon: for rare diseases Ltd

                                                               LAM Action

                                                               LifeArc

                                                               London & Partners Limited

                                                               PHTA Ltd

                                                               Ostique Limited

                                                               Adora Digital Health Ltd

                                                               Elem Biotech SL

                                                               Aplagon Oy

                                                               RSA (Holdings) Ltd

                                                               MedCity Ltd

 Historic directorships and partnerships in previous 5 years:  Karoo CGT Limited

                                                               Pricewaterhouse Coopers LLP

There is no further information to be disclosed in relation to the director
appointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM
Rules.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNUNVNRONUVUAR